We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dako; ONO Pharmaceutical Collaborate
News

Dako; ONO Pharmaceutical Collaborate

Dako; ONO Pharmaceutical Collaborate
News

Dako; ONO Pharmaceutical Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dako; ONO Pharmaceutical Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dako, an Agilent Technologies company, and ONO PHARMACEUTICAL CO., LTD. today announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer (NSCLC). This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

Lung cancer is the most common cause of cancer-related mortality worldwide, and is responsible for more than 1.5 million deaths per year(1). The demand for personalized medicine continues to increase, as it may provide a way to both improve patient care and better manage health care costs by targeting treatment to the individuals most likely to benefit from it.

"We are pleased to be chosen as ONO's partner for the development of a companion diagnostic test for this promising drug," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "Today's announcement follows several other collaborative agreements in the companion diagnostics area by Agilent's Dako business."

"We are delighted to collaborate with Dako, a global leader in diagnostics, and this partnership contributes to value maximization of Opdivo," said Gyo Sagara, president, representative director and CEO, ONO.

The financial details of the agreement were not disclosed.

Advertisement